A world-renowned expert in pharmacology, Prof. Youdim is the inventor and developer of the innovative Parkinson’s disease drug “Azilect”, Teva’s second largest innovative blockbuster, with annual revenues on $700M, and Selegiline, an MAO-B inhibitor for Parkinson’s disease treatment. Prof. Youdim has extensive experience in the pharmaceutical industry, professor emeritus at the Technion, where he was the head of the Department of Pharmacology at the Faculty of Medicine for over 30 years.
As an expert in the area of medical devices with vast experience in engineering and 3D modeling, Tal Youdim joined Youdim to support the technical aspect of the incubator’s work. In the past he has worked on development of mitral valve replacement & repair technology, Central venous catheter technology and drug device combinations. Today, he is responsible for all developments related to medical devices, drug administration devices and operations.
With extensive experience in the area of Technological incubators, Efrat has over 20-years experience with start-up companies, having served in various financial positions at incubators. Prior joining TerraLab, she served in various finance positions as CFO and Finance controller in Israeli companies such as Eltam Technological Incubator, Naiot Technological Center, L.N. innovative Technology Ltd and has rendered financial services to the project companies during and post the incubation period.
Avraham Hermon, MA, is a patent attorney with extensive experience in intellectual property (IP) prosecution and strategy. In addition to experience in private practice assisting universities and startups in the pharmaceutical field, Mr. Hermon has extensive experience in industry, where he headed a team that evaluated startups before in-licensing, and managed patent prosecution relating to innovative pipeline products and marketed pharmaceuticals.
Prof. Moussa Youdim, a world-renowned expert in pharmacology, is Youdim’s Chairman. Prof. Youdim is the inventor and developer of the innovative Parkinson’s disease drug “Azilect”, Teva’s second largest innovative blockbuster, with annual revenues on $700M, and Selegiline, an MAO-B inhibitor for Parkinson’s disease treatment. Prof. Youdim has extensive experience in the pharmaceutical industry, professor emeritus at the Technion, where he was the head of the Department of Pharmacology at the Faculty of Medicine for over 30 years.
Prof. Eliyahu Heldman, A professor emeritus at Ben-Gurion University, with over 40 years’ experience in neuroscience research, Prof. Heldman’s experience includes work at NIH and evaluation of CNS-active drugs at the Israel Institute for Biological Research. In 2003, he co-founded NeuroDerm Ltd., Israel (NASDAQ: NDRM). Prof. Heldman was also a co-inventor of Cevimeline (EvoxacTM), an FDA-approved muscarinic agonist, for the treatment of Sjögren’s syndrome. He has published over 130 scientific articles, is co-inventor of more than 10 patents and has edited two books on the subject of neuroactive drugs.
Prof. Martin Rabey, Prof. Rabey is board certified in general neurology, with a sub-specialty in Parkinson’s disease and Alzheimer’s disease. He is the former chair of the Department of Neurology at Assaf HaRofe Medical Center.
Prof. Peter Riederer, is a German neuroscientist with several thousands of citations and around 950 scientific writings. He has published more than 620 scientific papers in peer-reviewed scientific journals that are indexed in MEDLINE, the most referent biomedical scientific database. He has also been author and co-author of more than 20 books relevant to the fields of neuroscience, psychiatry and neurology.
Dr. Orly Weinreb is a leading neuroscientist and researcher, who took a major part in the research and development of Rasagiline (Azilect®) at the Eve Topf Center Technion, IL. She earned a BSc (hon.), MSc and DSc at Technion – Israel Institute of Technology, Haifa and is a Postdoctoral European Common fellow, Netherlands. She is currently CEO at Glaucopharm Ltd and a co-founder of N2B Ltd.